Proactive Investors
16 Jun 2026, 15:50 UTC · 14w ago
Verdict
Headline takes no side. We score RGPX +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Rhythm Pharmaceuticals reported that setmelanotide produced robust and sustained weight loss in patients with acquired hypothalamic obesity over a 2.5-year period.
More positive than 92% of claims this week
Rhythm Pharmaceuticals' bivamelagon therapy showed progressive reductions in BMI and hunger measures in acquired hypothalamic obesity patients at one year.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 77% of claims this week
Blockmate Ventures' 110-acre Wyoming site features dual fiber connectivity and proximity to a substation, supporting its suitability for AI data center development.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
Reported robust, sustained, and clinically significant weight loss results for setmelanotide and positive data for bivamelagon.
More positive than 73% of ticker scores this week
Chairman stated that the company's site meets key requirements for AI data centre development.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
7h ago
—
No price for RGPX right now — the quote feed didn't answer.
RGPX chart →
